Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support

BACKGROUND: Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19) patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill. We determined whether early (within 48 h) dexamethasone was associated with mortality in patients hospitalised with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Crothers, Kristina, DeFaccio, Rian, Tate, Janet, Alba, Patrick R., Goetz, Matthew Bidwell, Jones, Barbara, King, Joseph T., Marconi, Vincent, Ohl, Michael E., Rentsch, Christopher T., Rodriguez-Barradas, Maria C., Shahrir, Shahida, Justice, Amy C., Akgün, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841623/
https://www.ncbi.nlm.nih.gov/pubmed/34824060
http://dx.doi.org/10.1183/13993003.02532-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841623/
https://www.ncbi.nlm.nih.gov/pubmed/34824060
http://dx.doi.org/10.1183/13993003.02532-2021

Ejemplares similares